Login to Your Account

Cubist, Alnylam Partner in $102.5M RNAi Drugs Deal

By Donna Young

Monday, January 12, 2009
Massachusetts firms Cubist Pharmaceuticals Inc. and Alnylam Pharmaceuticals Inc. have formed a 50-50 North American partnership to develop and commercialize Alnylam's respiratory syncytial virus (RSV)-specific RNAi therapeutics. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription